ArticleMolecular diversity2026
Copper-catalyzed desulfurative guanylation of amines using CS
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Guanidine compounds constitute a significant class of nitrogen-containing organic molecules with widespread applications in medicinal chemistry and synthetic science. Herein, we report a copper-catalyzed desulfurization strategy for the efficient synthesis of guanidine derivatives directly from amines and carbon disulfide. This transformation hinges on the in situ generation of a thiourea intermediate of a thiourea intermediate, followed by copper-catalyzed desulfurization to afford a highly reactive carbodiimide intermediate, with molecular oxygen serving as a green terminal oxidant in the catalytic cycle. In contrast to conventional methodologies relying on hypervalent iodine reagents, this protocol circumvents the use of strong oxidants and exhibits broad substrate scope and excellent functional group tolerance. Notably, this approach is amenable not only to the construction of structurally diverse and complex guanidine derivatives but also to the late-stage functionalization of drug-related molecules.
Indexed as
Identifiers
42446861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.